Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on mental health treatments, announced that its CEO, Michael Halstead, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is scheduled to take place from September 14-16, 2026, in New York City. Halstead’s fireside chat will be webcast live on September 14 at 9 a.m. EDT, with a replay available on the company’s investor relations website.
The announcement comes at a pivotal time for Helus Pharma, which is developing novel serotonergic agonists (NSAs) designed to activate serotonin pathways believed to promote neuroplasticity. The company’s lead candidate, HLP003, is currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. These programs address significant unmet needs in mental health, where current treatments often have limitations in efficacy and durability.
The company’s participation in the H.C. Wainwright conference is significant because it provides a platform to showcase its clinical data and strategic vision to a broad audience of institutional investors, analysts, and industry stakeholders. With a growing pipeline and a focus on innovative mechanisms of action, Helus Pharma aims to differentiate itself in the competitive psychiatric drug market. The conference appearance could help the company attract potential partnerships or funding to accelerate its development programs.
Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland, and has an extensive research portfolio of investigational NSAs. The company’s commitment to developing therapies that provide durable improvements in mental health is underscored by its proprietary technology and clinical progress. As the company moves forward, the outcomes of its late-stage trials will be closely watched by investors and the medical community alike.
The fireside chat at the H.C. Wainwright conference offers an opportunity for attendees to gain insights into Helus Pharma’s strategy, upcoming milestones, and the potential impact of its therapies on the mental health landscape. Interested parties can access the live webcast and subsequent replay through the company’s investor relations website. For more information about Helus Pharma and its pipeline, visit www.helus.com or follow the company on social media platforms. The full press release is available at https://ibn.fm/1HSIo.
